IMMUPHARMA PLC — Board/Management Information 2018

Nov 1, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0704G

Immupharma PLC

01 November 2018

1 November 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

Nominated Adviser Status

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser ("NOMAD"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP. The Directors have also been informed that Northland has voluntarily agreed to relinquish its NOMAD status and will be removed from the register of NOMADs with effect from 7am (GMT) on 1 February 2019.

In accordance with AIM Rule 1, the Company is required to appoint a new NOMAD by 1 February 2019, if not, the Exchange will suspend trading in the Company's AIM Securities. If the Company does not appoint a replacement NOMAD by 4 March 2019, the admission of its AIM Securities will be cancelled. 

The Company has commenced the process to appoint a new NOMAD and will make a further announcement in due course.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

For further information please contact:

ImmuPharma plc (www.immupharma.co.uk)	+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
Northland Capital Partners Limited (NOMAD & Joint Broker) David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking Stanford Capital Partners (Joint Broker) Patrick Claridge Chris Coleman SI Capital (Joint Broker)                                                                      Nick Emerson	+44 (0)20 3861 6625 +44 (0) 20 3815 8880 +44 (0) 1483 413500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUGGQWGUPRGWG